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The class I PI3K/Akt pathway is critical for cancer
cell survival in dogs and offers an opportunity for
therapeutic intervention
Yu-Ting Chen, Karen AL Tan, Lisa Y Pang and David J Argyle*
Abstract
Background: Using novel small-molecular inhibitors, we explored the feasibility of the class I PI3K/Akt/mTORC1
signaling pathway as a therapeutic target in canine oncology either by using pathway inhibitors alone, in
combination or combined with conventional chemotherapeutic drugs in vitro.
Results: We demonstrate that growth and survival of the cell lines tested are predominantly dependent on class I
PI3K/Akt signaling rather than mTORC1 signaling. In addition, the newly developed inhibitors ZSTK474 and KP372-1
which selectively target pan-class I PI3K and Akt, respectively, and Rapamycin which has been well-established as
highly specific mTOR inhibitor, decrease viability of canine cancer cell lines. All inhibitors demonstrated inhibition of
phosphorylation of pathway members. Annexin V staining demonstrated that KP372-1 is a potent inducer of
apoptosis whereas ZSTK474 and Rapamycin are weaker inducers of apoptosis. Simultaneous inhibition of class I PI3K
and mTORC1 by ZSTK474 combined with Rapamycin additively or synergistically reduced cell viability whereas
responses to the PI3K pathway inhibitors in combination with conventional drug Doxorubicin were cell line-
dependent.
Conclusion: This study highlighted the importance of class I PI3K/Akt axis signaling in canine tumour cells and
identifies it as a promising therapeutic target.
Keywords: Canine, Cancer, PI3, AKT, MTOR, Therapeutic, Target
Background
The class I phosphatidylinositol 3-kinase (PI3K) signaling
pathway comprises a series of serine/threonine kinase
cascades that regulate a variety of cellular processes in-
cluding cell cycle progression, cell survival and migra-
tion, and protein synthesis. Recent evidence supports the
hypothesis that the dysregulation of class I PI3K signal-
ing promotes tumourigenesis and angiogenesis in various
cancer types [1-3].
Class I PI3K is predominantly activated by receptor tyrosine
kinases (RTKs) upon receiving growth factor stimulation. The
activated RTKs undergo either autophosphorylation of tyrosine
(Y) residues at the intracellular domains or phosphorylation of
their substrates such as IRS-1, IRS-2 and Gab on Y residues.
The phosphorylated Y residues are soon recognized by SH2
domains in p85 regulatory subunit of class I PI3K, recruiting
class I PI3K to plasma membrane, triggering activation of PI3K
downstream pathways (reviewed in ref. [4,5]). Alternatively, class
I PI3Ks can be activated through the interaction between p110
catalytic subunit and Ras following RTK activation [6-8]. The
activated class I PI3K can convert phosphatidylinositol-4,5–
biphosphate (PIP2) to phosphatidylinositol-3,4,5–triphosphate
(PIP3), resulting in the recruitment of Akt to the plasma mem-
brane and allowing phosphatidylinositol 3-dependent kinase 1
(PDK1) to phosphorylate and activate Akt. In contrast, Akt ac-
tivity can be counteracted by phosphatase and tensin homolog
(PTEN) tumour suppressor through conversion of PIP3 back to
PIP2 (reviewed in ref. [9]).
The class I PI3K effects cellular functions through its
two major downstream effectors Akt and mTOR. Akt can
phosphorylate FoxO3a, BAX, BAD, and caspase 9 to
antagonize apoptotic activity, [10-13] phosphorylate pro-
survival factors such as MDM2 and IKK-α to maintain cell
survival, [14,15] phosphorylate mitochondrial hexokinase-
II to prevent mitochondria from initiation of apoptosis,
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[16] phosphorylate GSK3 and cell cycle inhibitors p21WAF1
and p27KIP to promote G1/S cell cycle progression, [17-19]
phosphorylate tuberous sclerosis complex 2 (TSC2) or
PRAS40 to trigger mTOR complex 1 (mTORC1)-
mediated protein synthesis, [20,21] and phosphorylate tel-
omerase reverse transcriptase (TERT) to increase cell
longevity [22].
The mTOR kinase acts as an Akt substrate when mTOR
binds to Raptor to form mTORC1. But mTOR can become
an Akt upstream activator when mTOR binds to Rictor to
form mTOR complex 2 (mTORC2) (reviewed in ref. [23])
mTORC1 promotes protein synthesis through activation of
its two downstream pathways: p70S6 kinase (p70S6K)/S6
ribosomal protein (S6RP) pathway triggers translation of 5'
terminal oligopolypyrimidine (TOP) mRNAs encoding ribo-
somal proteins and elongation factors and eukaryotic trans-
lation initiation factor 4E (eIF4E)-binding protein 1 (4E-
BP1)/eIF4E pathway initiates cap-dependent translation
[24-30]. Accumulating evidence shows that regulation of
eIF4E activity is a two-step mechanism. Initially, active
mTORC1/4EBP1 signaling causes dissociation of eIF4E
from 4EBP1 binding, which in turn allows Erk and/or p38
MAPK-mediated MnK1 and Mnk2 to phosphorylate eIF4E
on ser209, consequently facilitating eIF4E to enter the eIF4F
complex and triggering cap-dependent translation [27-30].
The cap-dependent translation can synthesize proteins pro-
moting cell growth (e.g. cyclin D1 and c-Myc) and neovas-
cularization (e.g. VEGF, bFGF) and some malignant
behaviours associated with tumour progression (e.g. matrix
metalloprotease 9) (Figure 1) (reviewed in ref. [31,32]).
It has been reported that a variety of molecular alterations
in any component of the PI3K pathway and its upstream
signals can lead to constitutive activation of PI3K kinase
cascades. This includes mutations identified in genes encod-
ing RTKs such as mutant KIT-driven human and canine
mast cell tumours and mutant Flt3-driven leukemia [33-35].
Mutations of K-ras and N-ras genes have been documented
in canine lung cancer and canine leukemia respectively [36].
Aberrant expression of class I PI3K subunits, such as ampli-
fication of PIK3CA and mutation of PIK3R1, is commonly
found in colon cancer [37,38]. High frequency of PTENmu-
tation has been reported in malignant glioblastoma [39]. In
addition, post-translational modification of PTEN, leading
to down-regulation of PTEN activity, has been described in
T cell leukemia [40]. Alterations of three Akt isoforms, in-
cluding amplification of Akt1, somatic (activating) muta-
tions of Akt1,amplification of Akt2, overexpression of Akt2
without evidence of Akt2 amplification, overexpression of
Akt3 mRNA and protein but lack evidence of Akt3 amplifi-
cation, and somatic (activating) mutations of Akt3 have
been reported in a wide range of tumour types [41-46].
In this study, we examined the importance of the class I
PI3K/Akt pathway in promoting tumourigenicity of canine
cell lines by utilizing small molecules ZSTK474, KP372-1
and Rapamycin that selectively inhibit class I PI3K, Akt
and mTOR, respectively. Canine lines were treated with
these inhibitors and cell survival determined by CellTiter-
Glo assays and annexin V/PI staining, whilst activation of
PI3K/Akt/mTOR components were detected by western
blotting. This paper demonstrates that class I PI3K/Akt
signaling is critical for the viability of all canine cancer cell
lines studied. In particular, Akt-mediated anti-apoptotic
activity was found to be critical for maintaining cell viabil-
ity. Furthermore, we demonstrate that simultaneous inhib-
ition of class I PI3K and mTOR may offer a better
therapeutic approach for canine cancer therapy than the
concomitant treatment of the PI3K pathway in combin-
ation with conventional cancer cytotoxic drugs.
Results
Class I PI3K signaling is activated in canine cancer cells
To determine the extent of class I PI3K kinase pathway acti-
vation in these five canine tumour cell lines, we employed
western blot analysis to examine the presence of active
(phosphorylated) forms of several components of the class I
PI3K pathway, including phosphorylated Akt, mTOR, S6RP,
4EBP1 and eIF4E. In addition to these canine cell lines, the
human Jurkat T leukemic cell line was used as control as
the cell line has constitutive activation of class I PI3K signal-
ing through PTEN loss [47]. As shown in Figure 2, all ca-
nine lines with either PTEN expression (3132, SB, J3T and
C2 cells) or PTEN loss (REM cells) expressed detectable
levels of active forms of these proteins, indicating active
class I PI3K signaling in these canine cells.
Because accumulating evidence suggests cross-talk be-
tween class I PI3K and Ras/Raf/ERK MAPK pathways
commonly occurs (reviewed in ref. [48]), we explored the
activity of the ERK/MAPK pathway in these canine cells.
Our western blot results demonstrated that these canine
cells expressed detectable levels of active forms (phos-
phorylation) of ERK1/2, indicating Ras/ERK MAPK sig-
naling is also activated in these canine cells. However,
this was not detected in the human Jurkat cell line and
very low in the canine C2 cell line (Figure 2).
Inhibition of class I PI3K/Akt/mTOR signaling significantly
decreases the viability of canine cancer cell lines
To investigate the potential role of class I PI3K signaling in ca-
nine cell lines, we used specific chemical inhibitors to block
pathway components. Inhibitors used were ZSTK474, KP372-
1 and Rapamycin, which targeted pan-class I PI3Ks, Akt and
mTOR respectively. Subsequently, we compared cell viability
of drug-treated cells with those of vehicle-treated cells by using
a standard cell viability assay. While we recognize that colony-
forming assays represent a more robust method for measuring
responses to anti-cancer agents, this would have been imprac-
tical for such a large-scale cell study. As shown in Figure 3A,
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ZSTK474 at concentrations between 100 nM and 10 μM
exhibited a remarkable decline in cell viability by ≥74% with al-
most full inhibition in SB (96%) and in Jurkat T cells (100%).
However, the effect of this drug at concentrations between
10 μM and 40 μM appears to plateau in J3T, C2 and 3132 cells
with no further inhibition in REM and SB cells. In this study,
KP372-1 showed its efficient inhibition effects on all cell lines
causing 100% loss in cell viability after incubation with this
compound at the concentrations of≥250 nM for 2 days, com-
pared with ZSTK474 and Rapamycin which required a longer
period of time (3 days) and much higher doses (at micromolar
concentrations) to reach effective inhibition (Figure 3). Not-
ably, REM cells were most sensitive to KP372-1 with full inhib-
ition of cell viability at the concentration of≥62.5 nM.
With regard to Rapamycin, it was observed that the
doses within a nanomolar range had limited effects on
inhibiting the viability of these canine cells. Jurkat T cells
were observed to be most sensitive to Rapamycin (con-
centration for 50% inhibition (IC-50) of viability ~ 1nM)
whereas all canine cancer cell lines were relatively resist-
ant to Rapamycin and the IC50 values for canine 3132,
C2, SB, REM and J3T cells were 1 μM, 1-10 μM, 10 μM,
10-20 μM and> 20 μM, respectively. Among all lines,
canine J3T and REM cells were most resistant to Rapa-
mycin. The doses for Rapamycin to reach full inhibition
of all lines were between 20 μM and 40 μM (Figure 3C).
The concentrations required to inhibit the target via
western blot analysis correlated well with those to cause
cell killing via the viability assay.
The class I PI3K/Akt/mTOR inhibitors abrogate activity of
class I PI3K signaling
To study the inhibitory effects of ZSTK474, KP372-1 and
Rapamycin on the class I PI3K/Akt/mTOR axis signaling
in canine cells, we performed western blot analysis to
evaluate expression levels of active (phosphorylated) forms
of class I PI3K downstream effectors, including Akt, S6RP,
4EBP1 and eIF4E.
Western blot analysis demonstrated that ZSTK474 down-
regulated phosphorylation of Akt and mTOR downstream
targets S6RP and 4EBP1. However, there was no change in
phosphorylation of eIF4E (Figure 4A). KP372-1, at the con-
centration of 400 nM, down-regulated phosphorylation
levels of S6RP and 4EBP1 in all lines and eIF4E in J3T and
Figure 1 Schematic diagram of the class I PI3K/Akt/mTOR axis pathway. The targets of the inhibitors (ZSTK474, Wortmannin, KP372-1 and
Rapamycin) used in this study are indicated.
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REM cells. However, this inhibitor was observed to up-
regulate phosphorylation levels of eIF4E in Jurkat T cells
(Figure 4B). Rapamycin inhibited mTORC1 signaling, based
on decreased γ hyper-phosphorylation of 4EBP1 and phos-
phorylation of S6RP. But up-regulation of eIF4E phosphor-
ylation was observed in human Jurkat T cells upon
Rapamycin treatment (Figure 4C).
To dissect the dynamics of inhibition further, we per-
formed a time-course study utilizing the C2 cell line only.
As shown in Figure 5A, ZSTK474 and Wortmannin, both
of which are inhibitors targeting all isoforms of p110 subu-
nits of class I PI3K, blocked class I PI3K activity, as evi-
denced by significant reduction in phosphorylation levels of
Akt and its downstream substrates S6RP and the γ hyper-
phosphorylated form of 4EBP1 in C2 cells. However, com-
pared with Wortmannin, ZSTK474 showed greater potency
and greater duration of activity in down-regulating class I
PI3K kinase signaling. This was based on the results show-
ing that inhibition of phosphorylation of downstream ele-
ments of class I PI3K by ZSTK474 lasted for 50 hrs whereas
Wortmannin lasted for 12 hrs (Figure 5A). The efficacy of
Rapamycin in inhibiting mTORC1 signaling lasted for
50 hrs, as indicated by decreasing phosphorylation levels of
S6RP and γ hyper-phosphorylation form of 4EBP1. This is
consistent with previous studies suggesting that the efficacy
of Rapamycin can last for ~3 days [9].
For the time course study of KP372-1 in C2 cells, three
doses higher than the inhibitory concentration of 100%
cell viability (IC-100), including 150, 200 and 400 nM,
were tested. At the highest dose (400 nM), the phosphor-
ylation levels of PI3K/Akt substrates S6RP and 4EBP1
were decreased at 4 hrs. However, at 8 and 12 hours, this
dose demonstrated profound inhibition of phosphoryl-
ation of all PI3K downstream substrates, including Akt,
S6RP, 4EBP1 and eIF4E, (Figure 5B). KP372-1 at concen-
trations between 150 nM and 200 nM showed no inhibi-
tory effects on class I PI3K activity at the early time
points of 4 and 8 hrs but gradually down-regulated all of
its downstream components at later time points of 12,
21 and 24 hrs (Figure 5B). However, data of C2 cells
treated with 200 nM and 400 nM KP372-1 at later time
points 21 and 24 hrs were unavailable (Figure 5B).
Effects of class I PI3K/Akt/mTOR inhibitors on cell
apoptosis
To determine whether the three class I PI3K pathway inhi-
bitors ZSTK474, KP372-1 and Rapamycin induce apoptosis
in these canine lines, cells were stained with annexin V, a
cell apoptosis marker, and propidium iodide (PI), followed
by flow cytometry analysis. The results demonstrated that
ZSTK474 significantly increased apoptosis of Jurkat T, C2
and SB cells by 32%, 24% and 19%, respectively, as com-
pared with the controls (Figure 6B). Conversely, 3132, J3T
and REM cells were not affected by ZSTK474 treatment
and the increased apoptosis rate was below 6%. By contrast,
KP372-1 was shown to be a potent inducer of apoptosis
causing> 87% cell loss in most cell lines and 60% loss of SB
cells at the concentration of 400 nM for 1 day. Since Rapa-
mycin at 20 μM was observed to fully inhibit the viability of
most cell lines, except REM and J3T cells whose viability
rates were reduced by 65% and 48% respectively (Figure 3C),
it raised the question whether Rapamycin at such a high
dose (20 μM) could down-regulated cell viability through
triggering apoptosis. As shown in Figure 6B, apoptotic rates
were significantly increased by 20 μM Rapamycin in all lines
except J3T cells which was not affected by this drug treat-
ment regime.
Additive or synergistic inhibitory effects on cell viability
when ZSTK474 and Rapamycin were combined
We have demonstrated that Rapamycin inhibited canine
cell lines with IC50 values of between 1 and> 20 μM
(Figure 3C). Notably, 1 μM is higher than the recom-
mended concentration of Rapamycin or rapalogues that
are currently utilized to treat human (Cmax =~600 nM)
Figure 2 Western blot analysis of components of the class I
PI3K and ERK pathways in human and canine cancer cells.
Whole cell lysates (comprising 50 μg total protein) were subjected to
western blotting analysis with β-actin as a loading control.
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and canine cancer patients (Cmax =~10 nM) due to the
drug-related toxicity observed in human patients [49-
51]. To investigate whether concurrent inhibition of two
other pathway components could improve the efficiency
of Rapamycin, cells were concomitantly treated with
ZSTK474 and Rapamycin.
The inhibitory effect of drug combinations on cell via-
bility was evaluated using the Bliss additivism model
[52]. Briefly, if the cell viability rates generated by Bliss
additivism model analysis were higher than, overlapped
with, or lower than those rates obtained from experi-
mental results, it was assumed that the combination had
a synergistic, additive, or antagonistic effect, respectively.
As shown in Figure 7A, the Bliss analyses showed that
ZSTK474 combined with Rapamycin had an additive ef-
fect on most lines and even a synergistic effect on J3T
cells. In this study, this drug combination demonstrated
an increased efficacy of: 8-22% in Jurkat, 16-23% in
3132, 7-22% in SB, 0-10% in REM, 23-36% in J3T and
13-29% in C2, as compared with either Rapamycin or
ZSTK474 alone, depending on which single agent
achieved maximal inhibition of cell viability. Notably, ca-
nine J3T cells, as mentioned earlier (see Figure 3C), were
most resistant to Rapamycin but showed synergistic re-
sponse to the drug combination, suggesting that class I
PI3K/Akt signaling may be activating a cell survival path-
way other than mTOR.
Further, western blot analysis, demonstrated that
ZSTK474 alone or in combination with Rapamycin sig-
nificantly decreased the levels of phospho (p)-Akt in
most cell lines but moderately decreased p-Akt in C2
cells (Figure 7B). P-Akt levels in Jurkat T cells were
decreased by Rapamycin after incubation for a longer
time period (18 hrs). Similar effects of Rapamycin on
Jurkat T cells and other cell lines after exposure for
24 hrs, have been described in previous studies [53,54].
It was observed that the drug combination profoundly
inhibited the levels of p-4EBP1 but not p-S6RP as com-
pared with each drug alone. However, full inhibition of
p-4EBP1 did not contribute to down-regulation of p-
eIF4E. In Jurkat T cells, Rapamycin-induced phosphoryl-
ation of eIF4E was observed to be repressed by co-treat-
ment of Rapamycin in combination with ZSTK474.
Effects of the combination of the class I PI3K/Akt/mTOR
pathway inhibitors and Doxorubicin on SB and REM cells
To investigate the impact of inhibition of PI3K/Akt/mTOR
axis pathway on the chemosensitivity of canine tumours, we
evaluated the effects of the combination of the class I PI3K
pathway inhibitors and Doxorubicin on the viability of canine
Figure 3 Sensitivity of canine and human cancer cells to inhibitors targeting class I PI3K/Akt/mTOR pathway. Cells were treated with a
range of doses of the pan-class I PI3K inhibitor ZSTK474 for 3 days (A), Akt inhibitor KP372-1 for 2 days (B), or mTOR inhibitor Rapamycin for
3 days (C). After drug treatment, the number of viable cells was determined by using CellTiter-GloW Luminescent Cell Viability Assay. Results were
expressed as mean (±SD) counts of quadruplicate wells. The values of the viability rates of the drug-treated cells were compared with the vehicle
(DMSO)-treated cells on the same culture plates.
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SB and REM cells and utilized the Bliss additivism model to
analyze the effects. As shown in Figure 8, the Bliss analysis
showed that ZSTK474 antagonized the cytotoxic effects of
Doxorubicin in both cell lines. KP372-1 highly synergized
with the cytotoxic action of Doxorubicin in SB cells with an
increase in efficacy of 13-43%, as compared with treatment
with KP372-1 alone. There was antagonism between the
actions of KP372-1 with Doxorubicin in REM cells. Rapamy-
cin was observed to enhance Doxorubicin-induced cytotox-
icity in both cell lines in an additive manner with an increase
in efficacy of 2-23% in SB cells and 2-13% in REM cells as
compared with either Rapamycin or Doxorubicin alone.
Discussion
In the present study, we demonstrate that human and ca-
nine cancer cell lines express constitutively activated class
I PI3K/Akt/mTORC1 axis signaling, as evidenced by de-
tectable levels of phosphorylated forms of PI3K down-
stream effectors, including Akt, mTOR, S6RP, 4EBP1 and
eIF4E. Subsequently, we inhibited the class I PI3K pathway
at different levels by utilizing small molecules inhibitors
ZSTK474, KP372-1 or Rapamycin to specifically target
pan-class I PI3K, Akt and mTOR respectively. Previous
studies have demonstrated ZSTK474 to have ~11, ~24,
and ~27 fold specific inhibition for class I PI3Kα over class
II PI3K-C2β, mTOR and DNA-dependent protein kinase
(DNA-PK), respectively [55,56]. Moreover, this inhibitor is
reported to have weak or no inhibitory effects on activities
of class II PI3K-C2α, class III PI3K, and PI4K. In addition,
ZSTK474 did not down-regulate phosphorylation of ERK
and activities of several components of MAPK pathway
[55-58]. Therefore, our results suggest that the viability of
the cell lines tested is, in part class I PI3K-dependent.
However, we also observe that ZSTK474 fails to fully in-
hibit cell viability in most canine cell lines, suggesting the
existence of another mechanism for cell survival. The ac-
tive ERK signaling detected in these canine cells may play
a role in resistance to PI3K pathway inhibition.
Western blot analysis demonstrated that ZSTK474 inhi-
bits the class I PI3K/Akt/mTOR axis signaling. Analysis of
apoptosis revealed that ZSTK474 is less potent at apoptosis
induction than KP372-1 or Rapamycin, suggesting that
ZSTK474 does not inhibit cell viability entirely through in-
duction of apoptosis. A recent study of human cancer cell
lines showed that ZSTK474 has potent effects on arrest of
cell cycle progression through inhibition of phosphorylation
or expression of Akt and/or mTORC1 substrates, such as
p-GSK3β, p-mTOR, p-p70S6K and cyclin D1. However,
ability to induce apoptosis is cell line dependent and is con-
sidered, in general, a weak inducer of apoptosis [56]. Our
Figure 4 Effects of the inhibitors on class I PI3K/Akt/mTOR axis signaling in canine and human cancer cells. Cells were seeded at a
density of 20,000 cells per ml overnight, followed by treatment with 1 μM ZSTK474 (A), 400 nM KP372-1 (B), or 100 nM Rapamycin (C) for 5 hrs.
Whole cell lysates (comprising 50 μg total protein) were subjected to western blot with the indicated antibodies. β-actin was used as a loading
control.
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study suggests that class I PI3K is critical to the viability of
cancer cell lines but implicates the mechanism of ZSTK474
to be through inhibition of Akt/mTORC1-mediated protein
synthesis and cell growth rather than apoptosis induction.
In this study, KP372-1 is observed to be the most potent
drug to down-regulate cell viability, indicating the critical
role for Akt in these cell lines. Western blot analysis
demonstrated that high doses or long drug exposure of
KP372-1 is required to inhibit Akt/mTORC1 signaling com-
pared to ZSTK474 and Rapamycin. However, KP372-1
showed remarkable efficacy for inducing apoptosis. A previ-
ous study of KP372-1 on acute myelognous leukemia
(AML) suggests that this drug predominantly acts on inhib-
ition of PDK1/Akt-mediated anti-apoptosis mechanism but
has no function on arresting cell cycle progression [59]. In
agreement with this study, our data suggests that KP372-1
is a potent inducer of apoptosis through down-regulation of
Akt-mediated survival mechanism but has less effect on in-
hibition of Akt/mTORC1-mediated activities such as pro-
tein synthesis and cell cycle progression. In addition, as
REM cells are highly sensitive to KP372-1 but relatively re-
sistant to Rapamycin, it is suggested that Akt-mediated
anti-apoptosis activity, not mTORC1 activity, is critical for
the viability of REM cells. In the time course study of C2
cells, we find that KP372-1 at 400 nM initially down-regu-
lates phosphorylation of mTORC1 substrates S6RP and
4EBP1, and then gradually down-regulates phosphorylation
of Akt and eIF4E. We show that 400 nM KP372-1 induces
most C2 cells to apoptosis after 24 hours of incubation, in-
dicating the correlation of protein loss with apoptosis. The
down-regulated phosphorylation of Akt and eIF4E may be a
late event of de-phosphorylation of all protein kinases when
Figure 5 Effects of the inhibitors on class I PI3K/Akt/mTOR axis signaling in canine C2 cells. Cells were treated with pan-class I PI3K
inhibitor Wortmannin (W) at 1 μM and ZSTK474 (Z) at 1 μM, mTOR inhibitor Rapamycin (R) at 100 nM (A) and Akt inhibitor KP372-1 at 0, 150, 200
and 400 nM (B) for the indicated period of time. Whole cell lysates (comprising 50 μg total protein) were subjected to western blot with the
indicated antibodies. β-actin was used as a loading control. N/A indicates data unavailable due to induction of apoptosis in all cells.
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most cells undergo apoptosis. In addition to C2 cells,
decreased phosphorylation of all class I PI3K substrates is
also observed in KP372-1 treated REM and J3T cells.
The effects of Rapamycin on the viability of canine cells
tested in this study and the apoptosis results are in agree-
ment with previous findings that higher doses (micromolar
Figure 6 (See legend on next page.)
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ranges) of CCI-779 or Rapamycin can overcome drug re-
sistance mechanism and achieve full inhibition of cell pro-
liferation through the inhibition of mTORC2-mediated
Akt and ERK survival pathways and the profound inhib-
ition of global protein synthesis [60,61]. Accumulating evi-
dence suggest that Rapamycin at lower doses (nanomolar
range) requires initial interaction with cytoplasmic recep-
tor FKBP12, which in turn allows Rapamycin to bind
mTORC1, leading to inhibition of mTORC1 pathway but
also generation of drug resistance [60,61]. So far, at least
three mechanisms have been reported to be associated
with Rapamycin-resistance and all of them are linked to
mTORC1 inhibition. First route is through inhibition of
mTORC1/p70S6K, which in turn releases the feedback
loop of p70S6K/IRS-1/PI3K/Ras and stimulates Ras/ERK
MAPK and PI3K/Akt pathways [62-64]. The second route
is through inhibition of mTORC1, which in turn activates
expression of insulin-like growth factor-1 (IGF-1) and
IRS-2, followed by activation of IGF-1/IGF-1 RTK/IRS-2/
PI3K with a consequence of activation of the PI3K/Akt
pathway [65]. The third route is through mTORC1 inhib-
ition, followed by activation of the c-SRC/RTK pathway
and subsequent activation of the Ras/ERK MAPK pathway
[66]. Our western blot data show that low doses (100 nM)
of Rapamycin inhibits mTORC1 signaling but stimulates
phosphorylation of eIF4E in Jurkat T cells. As eIF4E phos-
phorylation is under the control of ERK and/or p38
MAPK pathways following mTORC1-mediated dissoci-
ation from 4EBP1, it is suggested that Rapamycin at the
low dose stimulates ERK or p38MAPK/Mnk/eIF4E path-
way in Jurkat T cells through any of the three Rapamycin-
resistance mechanisms described above [27-30]. Indeed, a
previous study of a PIM inhibitor has demonstrated that
inhibition of p70S6K activity in Jurkat T cells triggers a
p70S6K/IRS-1 feedback loop and activates Ras/MAPK sig-
naling [67]. In this study, we find that both Rapamycin
and KP372-1 significantly increase phosphorylation of
eIF4E in this cell line and the Rapamycin-induced phos-
phorylation of eIF4E in Jurkat T cells is suppressed by
Rapamycin in combination with ZSTK474. Another study
has reported that Rapamycin-induced eIF4E phosphoryl-
ation can be reversed by the combination of Rapamycin
and a PI3K inhibitor but, in certain cell lines, PI3K inhibi-
tor alone can still increases eIF4E phosphorylation [63].
This suggests that tumour cells can escape cell death
through additional mechanisms other than the p70S6K/
IRS-1/PI3K/Ras feedback loop. Due to simultaneous in-
hibition of both class I PI3K and mTORC1 reversing
Rapamycin-induced eIF4E hyper-phosphorylation, it is
suggested that Jurkat T cells are resistant to Rapamycin
through either activating the p70S6K/IRS-1/PI3K/Ras or
IGF-1/IGF-1 RTK/IRS-2/PI3K pathways, but not through
the third resistant mechanism that is the c-SRC/RTK path-
way [62,65,66].
By contrast, Rapamycin at higher doses (micromolar
range) directly binds to mTOR, which in turn inhibits
mTORC2 and global translation processes, leading to a dra-
matic decline in cell viability [61]. A recent study shows that
inhibition of mTORC2 by silencing expression of the Rictor
subunit can not only down-regulate Akt signaling but can
also down-regulate ERK phosphorylation [60]. In this study,
we have shown that Rapamycin at a high dose such as
20 μM significantly increases apoptotic rates of most cell
lines, confirming that reduction of cell viability was in part
through apoptosis. Hence, our data support previous find-
ings that high doses of Rapamycin decrease global transla-
tion processes and down-regulate mTORC2 activity [61].
Notably, mTORC2 has recently been identified as activators
of not only Akt survival kinase but also serum- and gluco-
corticoid-induced protein kinase (SGK), a pro-survival fac-
tor, and protein kinase C (PKC) [68-70]. This implicates a
role of mTORC2 in promoting survival of these canine can-
cer cell lines tested in the present study.
It is suggested that the mechanism for the additive or syn-
ergistic effects of ZSTK474 and Rapamycin on cells is
through simultaneous inhibition of Akt activity and inhib-
ition of mTORC1 activity. However, this drug combination
has no effects on eIF4E phosphorylation, in agreement with
previous findings that eIF4E phosphorylation is regulated by
ERK or/and p38MAPK pathways. Interestingly, we observed
that this drug combination does not profoundly inhibit
phosphorylation of S6RP in most canine cells except C2
cells. As S6RP has been reported to have three upstream
activators, which are PDK1/p70S6K, mTORC1/p70S6K and
Ras/ERK/RSK pathways, it is suggested that Ras/ERK/RSK
is most likely to contribute to the maintenance of S6RP
phosphorylation after blockade of both PI3K and mTORC1
signaling in these four canine cell lines [71-73]. Because
simultaneous inhibition of class I PI3K and mTOR by the
drug combination can result in down-regulation of PDK1-
and mTOR-mediated phosphorylation of PDK1, it is pos-
sible that active ERK signaling which is detected in these
(See figure on previous page.)
Figure 6 Effects of ZSTK474, KP372-1 and Rapamycin on induction of apoptosis. Cells were treated with 20 μM ZSTK474 for 2 days, 400 nM
KP372-1 for 1 day, 20 μM Rapamycin for 2 days, or vehicle control as described in Materials and Methods. Induction of apoptosis was determined
by annexin V/propidium iodide (PI) staining and flow cytometry analysis. Scatter pots with percentages of live, early apoptosis and late apoptosis
were indicated at lower left, lower right and upper right quadrants, respectively in A while B demonstrates this data in a bar chart format. This
data is representative of two independent experiments.
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canine cell lines may support S6RP activity and thus provide
an explanation for the limited effects of Rapamycin in the
down-regulation of S6RP phosphorylation in some lines
such as 3132. In Jurkat T cells, chronic exposure to Rapa-
mycin down-regulates both mTORC1 signaling and Akt
phosphorylation, which may provide an explanation for the
high sensitivity of Jurkat T cells to Rapamycin. Taken to-
gether, the additive/synergistic effects of ZSTK474 com-
bined with Rapamycin suggest the resistance of these
canine cells to Rapamycin alone, is due to active Akt and
ERK survival pathways.
In summary, our data demonstrates that the class I PI3K/
Akt/mTOR pathway is a major signaling axis in the survival
of cancer cells. We show that ZSTK474 and KP372-1 effect-
ively down-regulate cell viability, and highlight the critical
role of Akt activity in promoting the proliferation and sur-
vival of cells. Further, we show that ZSTK474 and KP372-1
inhibit cell viability via different mechanisms. ZSTK474 ef-
fectively down-regulates mTORC1 signaling but has weak
potency in apoptosis induction. KP372-1 has remarkable effi-
cacy for apoptosis induction but has weak potency on
mTORC1 inhibition. Rapamycin at nanomolar concentra-
tions has cytostatic effects. In contrast, Rapamycin at micro-
molar doses shows cytotoxic effects, suggesting mTORC2
inhibition effectively inhibits the viability of canine cancer
cells. We also show that ZSTK474 can enhance the effects of
Rapamycin on reducing cell viability, by inhibition of Akt
pathways. However, despite the additive or synergistic effects,
the overlapping toxicities of these drugs would need to be
resolved in a clinical setting. Our data suggest that the effect
of combining inhibition of the PI3K/AKT pathway with con-
ventional drugs such as doxorubicin is cell line dependent.
However, dissecting this synergistic mechanism may offer an
opportunity to identify cancer patients where this approach
may be beneficial.
Conclusion
In conclusion, the results of the present study support the
development of canine cancer therapy specifically target-
ing class I PI3K/Akt pathway. This study also implicates
mTORC2 as a potential target for canine cancer treat-
ment. As such mTORC2 deserves further investigation to
clarify the correlation of its downstream targets with
tumour survival mechanism. In addition, the current data
implicate the Ras/Raf/MEK/ERK pathway in resistance
mechanisms to class I PI3K pathway inhibitors, supporting
recent studies which generally recommend the use of
combinatorial inhibitors targeting both PI3K/Akt signaling
and Ras/ERK signaling [74,75].
Methods
Cell lines and tissue culture
Jurkat T (human T lymphoblast-like cells), 293 T (human
embryonic kidney 293 cells containing the SV40 Large
T-antigen), 3132 (canine lymphoma of B-cell origin), REM
(canine mammary carcinoma), SB (canine hemangiosar-
coma), J3T (canine glioma) and C2 (canine mast cell
tumour) cells, were used in this study. The Jurkat T, 3132,
REM and J3T cells were grown in RPMI 1640 (11835,
Gibco, Invitrogen, Paisley, UK), RPMI 1640 (11835, Gibco,
Invitrogen, Paisley, UK), DMEM (41965, Gibco, Invitrogen,
Paisley, UK) and DMEM (41966, Gibco, Invitrogen, Paisley,
UK) media respectively, all of which contained 10% (v/v)
fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/
ml streptomycin. The C2 cell line, provided by Dr. Richard
Elders, The Royal Veterinary College, London, was grown
in Minimum Essential Medium Eagle (M5650, Sigma-
Aldrich, Ayrshire, UK) medium containing 5% FBS, 1%
non-essential amino acid mix (NEAA) (Sigma-Aldrich, St
Louis, MO, USA), 1% GlutaMAX-1 (Invitrogen, Paisley,
UK), 50 μg/ml gentamicin. The SB cell line was grown in
EBM-2 (CC-3135, Lonza, Walkersville, MD, USA) supple-
mented with 2% FBS and EGM-2 SingleQuots (CC-4176,
Lonza, Walkersville, MD, USA) kit containing 0.04% hydro-
cortisone, 0.4% hFGF, 0.1% VEGF, 0.1% R3-IGF-1, 0.1% as-
corbic acid, 0.1% hEGF, 0.1% GA-1000 and 0.1% heparin.
Drug compounds and pathway inhibitors
ZSTK474 (pan-PI3K inhibitor, Z-1066, LC Laboratories,
USA), Wortmannin (pan-PI3K inhibitor, 1232, Tocris
bioscience, USA), KP372-1 (Akt inhibitor, B-0102, Ech-
elon, USA) and Rapamycin (mTOR inhibitor, R0395,
Sigma-Aldrich, USA) were dissolved in dimethyl sulfox-
ide (DMSO) as concentrated stocks that were stored at
-70 °C and diluted freshly in cell medium before use.
Doxorubicin was purchased from Pharmacia, Pfizer Ser-
vice Company (Zaventem, Belgium) and was soluble in
water.
(See figure on previous page.)
Figure 7 Effects of ZSTK474 in combination with Rapamycin on cells. Cells were treated with the indicated doses of ZSTK4747, Rapamycin,
the combination of the former two inhibitors or vehicle control for 3 days. Additive, synergistic, or antagonistic inhibitory effects of the drug
combination on cell viability were determined when the experiment values (cell viability percentages) of the drug combination were overlapped
with, lower than, or higher than Bliss theoretical values respectively (A). Western blot analysis was performed to determine the inhibitory effects of
ZSTK474 in combination with Rapamycin on class I PI3K activity (B). Cells were seeded at a density of 20,000 cells per ml overnight, followed by
treatment with 5 μM ZSTK474 (10 μM ZSTK474 in REM cells), 100 nM Rapamycin, the combination of the former two inhibitors or vehicle control
for 18 hrs. Whole cell lysates (comprising 50 μg total protein) were subjected to western blot with the indicated antibodies. β-actin was used as a
loading control.
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Cell viability assay
Cells were seeded at a density of 3 × 103 cells per well in
96-well plates overnight at 37 °C with 5% CO2, followed
by incubated with various doses of either single agent or in
combination with other drugs, or DMSO vehicle for a
period of time. All experiments were performed in at least
three replicates. After the drug treatment, the number of
viable cells was determined by using CellTiter-GloW Lumi-
nescent Cell Viability Assay (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. This
commercial kit quantified cell viability by measuring the
amount of ATP released from viable cells. The more viable
Figure 8 Effects of the combination of the class I PI3K/Akt/mTOR pathway inhibitors and Doxorubicin on cell viability. SB (A) and REM
(B) cells were treated with the indicated does of the class I PI3K/Akt/mTOR pathway inhibitors, Doxorubicin, the combination of the former two
drugs or vehicle control for 3 days (2 days for KP372-1). Additive, synergistic or antagonistic inhibitory effects of the drug combination on cell
viability were determined when the experiment values (cell viability percentages) of the drug combination were overlapped with, lower than, or
higher than Bliss theoretical values respectively.
Chen et al. BMC Veterinary Research 2012, 8:73 Page 12 of 15
http://www.biomedcentral.com/1746-6148/8/73
cells were present, the more ATP released and the higher
the value of luminescence detected.
Analysis of apoptosis and cell death
Cells were plated at a density of 3 × 104 cells per ml and
incubated overnight at 37 °C with 5% CO2. After that,
cells exposed to treat with 20 μM ZSTK474 for 2 days,
400 nM KP372-1 for 1 day, 20 μM Rapamycin for 2 days
or vehicle control were collected for apoptosis analysis
by using FITC Annexin V Apoptosis Detection Kit I
(556547, BD Pharmingen™, San Diego, CA, USA). In
brief, harvested cells were washed with cold PBS and re-
suspended in 100 μl of 1x Binding Buffer, followed by
stained with FITC Annexin V antibody and propidium
iodide (PI) for 15 min in the dark at room temperature,
according to the manufacturer’s instructions. Cells were
analyzed by flow cytometry using FACS Calibur Flow
Cytometer and CellQuest software (BD Biosciences, San
Jose, California).
Preparation of cell lysates and western blotting
Cells were seeded at a density of 20,000 cells per ml over-
night at 37 °C with 5% CO2, followed by incubated with
various doses of either single agent or in combination with
other drugs, or DMSO vehicle for a period of time. After
the drug treatment, cells were harvested and washed in cold
PBS, followed by lysed in 1% NP40 buffer containing
150 mM KCl, 25 mM Hepes (pH 7.4), 5 mM DTT, 50 mM
NaF, and 1 x Complete Mini Protease Inhibitor Cocktail
Tablet (Roche, Mannheim, Germany). The protein extracts
were quantified by using Quick Start Bradford Protein
Assay (Biorad Laboratories, CA, USA) according to the
manufacturer’s instruction. 50 μg protein specimens were
subjected to the SDS-PAGE, followed by transferred onto
nitrocellulose membranes. The membranes were immuno-
blotted with primary antibodies specific for PTEN, phos-
phor (p)-Akt (Ser473), mTOR, p-mTOR (Ser2448), p-S6RP
(Ser235/236) and p-4E-BP1 (Thr37/46), all of which were
purchased from Cell Signaling Technology (Danvers, MA,
USA) and were diluted 1:1000 in blocking buffer which was
made up of 1X phosphate buffered saline (PBS) solution
containing 5% skimmed milk and 0.1% Tween-20 and p-
eIF4E (Ser209) and β-actin, both of which were purchased
from Abcam (Cambridge, UK) and were diluted 1:5000 and
1:3000 respectively in blocking buffer. Subsequently, the
immunoblots were probed with either swine anti-rabbit
horseradish peroxidase (HRP) conjugated secondary anti-
body (1:1000) or rabbit anti-mouse HRP conjugated second-
ary antibody (1:2000 for detection of β-actin), both of which
were purchased from DAKO (Glostrup, Denmark) The
blots were developed using Amersham ECL Western Blot-
ting Detection Reagents (GE Healthcare, Buckinghamshire,
UK) and protein bands were visualized on autoradiography
film Hyperfilm (GE Healthcare, Buckinghamshire, UK). All
antibodies have previously been validated for canine pro-
teins [51].
Analysis of drug combination effect
The inhibitory effect of two drug combination on cell viabil-
ity was defined as additivity, synergy and antagony by using
Bliss additivism model. The methods of Bliss analysis was
adopted from Buck E, et al. [52] Hypothetical curve was
generated by using the equation Ebliss =EA+EB – (EA x EB).
While EA represented the percentage of decreased cell via-
bility by drug A, EB represented the percentage of decreased
cell viability by drug B. Therefore, if the cell decreased via-
bility (%) of the combination of the two drugs experimen-
tally was greater than Ebliss, the effect of the combination
was considered to be synergistic. On the contrary, if the per-
centage of decreased viability obtained by an experiment
was less than Ebliss, the effect of the combination would be
considered to be antagonistic. In the present study, the Bliss
additivity curves were generated by the combination of vari-
ous doses of drug A and a constant dose of drug B.
Statistical analysis
For cell viability assays, the values obtained from cell via-
bility assay, as shown in the figures, were compared with
the vehicle control on the same culture plates, followed
by expressed as percentages of mean values with stand-
ard deviations of at least three replicates.
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